Close Menu

JP Morgan Healthcare Conference

Applications for the rare-cell capture and sequencing service include the detection and monitoring of circulating tumor cells "and also, potentially, fetal diagnostics."

With a new LabChip platform and tissue imaging capabilities, Caliper has its eye on expanding in molecular diagnostics and targeting companion diagnostic deals as its personalized medicine strategy evolves.

On Wednesday, LabCorp talked about genetic counselors gained through the Genzyme Genetics acquisition, Bruker talked diagnostics, and Myriad addressed its plans for Europe and companion diagnostics.

Luminex will be going after a piece of the newborn screening market, estimated to be a $100 million-plus opportunity, with a new assay slated for an initial launch in Europe later this year.

Thermo Fisher Scientific, Pacific Biosciences, and Qiagen presented investors with views on the M&A market and technology development in the sequencing and molecular diagnostics industries.

The company has spoken to a number of firms operating in the MDx space at the JP Morgan conference, both large and small, "to avail ourselves to them."

Company officials see the potential for Life Tech's sequencing and qPCR platforms in developing new molecular diagnostic tools that could potentially supplant other technologies, including arrays.

The Ion 316 Semiconductor Sequencing Chip, which replaces the Ion 314, will be available to early-access customers in the first quarter.

"Over time, there is no reason why we can't build an instrument that costs $50,000, $100,000, $300,000, so we have got a tremendous portfolio opportunity ahead of us over time," a PacBio official said.

Waters, Genomic Health, Bio-Rad, Agilent, and Sigma-Aldrich were among the presenters on the first day of the conference.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.